Since deletion of chromosome 13q is a clinically relevant feature in multiple myeloma (MM), we analyzed bone marrow plasma cells from 29 patients with monoclonal gammopathy of undetermined significance (MGUS) to investigate the chromosome 13 status in MGUS. Studies were performed by interphase fluorescence in situ hybridization (FISH) with a panel of 13q14-specific probes (RB1, D13S319, D13S25, D13S31). Plasma cells with a deletion of at least one of the 13q14 loci were detected in 13 patients (44.8%) with MGUS. In five patients (17.2%), deletions of all four 13q14-specific probes were observed, and the additional deletion of a 13q telomeric region (D13S327) suggested loss of the entire 13q arm or monosomy 13. Loss of 13q14 was observed to be monoallelic and to occur in 11.0 to 35.0% of plasma cells (cut-off levels for a deletion Ͻ10% with all probes). Nine of 17 patients (52.9%) with MM progressing from a pre-existing MGUS had evidence for a deletion of 13q14 as determined by FISH with the RB1 probe. These results suggest that deletion of 13q14 is an early event in the development of monoclonal gammopathies, but its role for the eventual progression to MM remains to be determined prospectively. Leukemia (2000Leukemia ( ) 14, 1975Leukemia ( -1979 
Introduction
There is now increasing evidence that development of plasma cell malignancies is a multistep process already beginning at the level of monoclonal gammopathy of undetermined significance (MGUS). 1 However, molecular events occurring in MGUS plasma cells and ultimately leading to progression to multiple myeloma (MM) in a sizeable fraction of patients are still poorly characterized.
As far as chromosomal abnormalities are concerned, it has become evident over the past few years that virtually all patients with MM are cytogenetically abnormal. 2 Moreover, cytogenetics has emerged as an important prognostic parameter in MM, in particular deletions of chromosome 13q, which are predictive for short survival of patients with MM after conventional-dose and high-dose chemotherapy. [3] [4] [5] [6] MGUS is more difficult to study by metaphase cytogenetics than MM, and only few abnormal karyotypes from patients with MGUS have been reported. 7 Recent results obtained by interphase fluorescence in situ hybridization (FISH), however, indicate that aneuploidy of chromosomes 3, 7, 9, 11, 15, 18 , and X is present in at least 50% of patients with MGUS. [8] [9] [10] In the present study, we addressed the question of chromosome 13q deletions in plasma cells from patients with MGUS. Due to the limited number of plasma cells present in the bone marrow of patients with MGUS, we focused on chromosomal band 13q14, since in MM genetic loci in this chromosomal region were reported to be most commonly affected by deletions of 13q.
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Materials and methods
Patients
We investigated bone marrow (BM) specimens of 29 patients meeting the diagnostic criteria of MGUS as previously defined. 12, 13 Median age of patients was 70.5 years (range, 37-95 years), and the paraprotein was IgG in 22 patients, IgA in six patients, and IgM in one patient. BM plasma cells were below 5% in 22 patients, and between 6 and 10% in seven patients. Median follow-up of patients with MGUS was 25 months (range, 1-156 months).
In addition, 17 patients with MM, who had a previous history of MGUS, were included in this study. In seven of these patients, BM cells were also available from the time when the disease was still classified as MGUS.
Cells
BM aspirates were obtained from the posterior iliac crest or sternum and collected in a heparinized syringe. All procedures were done for diagnostic purposes, and informed consent according to institutional guidelines was obtained for the use of an aliquot of the specimens for research purposes. After dilution with phosphate-buffered saline (PBS), mononuclear BM cells were separated by density gradient centrifugation over Ficoll-Hypaque (density = 1.077; Sigma, St Louis, MO, USA). Mononuclear cells were washed twice with PBS, treated with Carnoy's fixative (methanol/glacial acetic acid 3:1 (vol/vol)), and stored at −20°C or −80°C.
Interphase FISH studies
The following DNA probes specific for distinct loci at chromosomal band 13q14 were used (Figure 1 represents a schematic diagram):
14 retinoblastoma gene-1 (RB1), D13S319, D13S25 (all purchased from Vysis, Downers Grove, IL, USA), and D13S31 (kindly provided by J Shaughnessy, University of Arkansas for Medical Sciences, Little Rock, AR, USA). All probes were directly conjugated with Spectrum-Orange. In addition, a probe specific for the D13S327 locus at the 13q telomere (Vysis) was utilized.
Hybridizations were performed as dual-color FISH assays combining each chromosome 13-specific probe with a probe specific for the centromeric region of chromosome 11 (conjugated with Spectrum-Green; Vysis) to control for Schematic diagram of the 13q14-specific probes used in this study (adapted from Kalachikov et al 14 ) .
hybridization efficiency. Chromosome 11 was included as a reference probe, since by FISH, it has not been found to be monosomic in MGUS; [8] [9] [10] in addition, monosomy 11 is a rare event in MM, both by metaphase cytogenetics and interphase FISH. 2, 15 To specifically study BM plasma cells, FISH and staining of cytoplasmic immunoglobulins (cIg) was simultaneously performed as previously described. 16 Only cIg-positive plasma cells with у2 signals with the chromosome 11 reference probe were evaluated for hybridization signals of the chromosome 13 specific probes. At least 100 cIg-positive cells were scored with a Zeiss Axioplan-2 immunofluorescence microscope equipped with an appropriate filter set (Zeiss, Jena, Germany) to visualize red, green, and blue immunofluorescence.
Cut-off levels to distinguish between background and true aneuploidy were derived from experiments with control specimens. These included three specimens from normal BM donors (kindly provided by Dr H Greinix, Bone Marrow Transplantation Unit, University of Vienna, Vienna, Austria) as well as BM specimens from patients with Hodgkin's disease and non-Hodgkin's lymphoma without histological evidence for BM involvement. From three of these control BM specimens, plasma cells were evaluated separately as described above. We also studied reactive plasma cells which were obtained from the peripheral blood of a patient with severe bacterial sepsis (30% of peripheral blood leukocytes consisted of plasma cells).
Statistical analysis
Chi-square test and t-tests were used for the statistical evaluation of results.
Results
Control specimens
To obtain cut-off levels for the presence of a deletion with any of the probes used in this study, we hybridized these probes to normal BM specimens and recorded the frequency of cells with just one hybridization signal. BM plasma cells were selectively evaluated in three of the normal BM specimens as well as reactive plasma cells from the peripheral blood of a patient with bacterial sepsis. These results are summarized in Table 1 . As can be seen from these results, frequency of cells with one hybridization signal with a 13q-specific probe was similar between the entire BM cell population and the plasma cells.
Aneuploidy by FISH in a test specimen is generally defined as the frequency of abnormal cells above the mean plus three standard deviations of the respective non-disomy observed in normal cells. For individual 13q-specific probes, cut-off levels ranged between 3.5% and 8.1% (Table 1) . Due to the limited number of plasma cells evaluable from patients with MGUS, we further increased the cut-off level and defined the observation of one hybridization signal with any probe in more than 10% of plasma cells as evidence for the presence of a deletion.
Deletions of 13q in plasma cells from patients with MGUS
Using interphase FISH analysis, we observed a deletion of at least one of the 13q14-specific chromosomal regions in 13 of 29 patients (44.8%) with MGUS ( Figure 2 ). RB1 was found to be deleted in nine patients, D13S319 and D13S25 in eight patients each, and D13S31 in five patients. In five patients (17.2%), there was loss of all four 13q14-specific loci; in these patients, we also noted a deletion of the 13q telomeric region (D13S327) suggesting loss of the entire 13q arm or monosomy 13. Deletions were always observed to be monoallelic, occurring in 11 to 35% of the cIg-positive plasma cells ( Table 2) .
Presence of a 13q deletion was independent of the paraprotein (IgA vs non-IgA; P = 0.86); also, there was no correlation with the percentage of BM plasma cells (5 ± 3% BM plasma cells in MGUS patients with a deletion of 13q14 vs 4 ± 2% in patients with normal chromosome 13 by FISH; P = 0.20) or the serum level of the M-protein (19.4 ± 7.7 g/l in Table 1 FISH results with control specimens RB1 D13S319 D13S25 D13S31 Tel13 
Figure 2
Summary of the FISH results observed in 29 patients with MGUS. Deletions, illustrated with black boxes, were detected in 13 patients, either as small interstitial deletions or large deletions, which also involved the 13q telomeric region (Tel 13) in five patients. --16  25  ----17  --12  --18  22  ----19  13  ----20  23  35  20  23  22  23  21  21  18  19  19  25  -22  ---28  21  22  13  24  18 a Patient numbers correspond to those as shown in Figure 2 .
patients with a deletion of 13q14 vs 16.3 ± 6.4 g/l in patients with normal chromosome 13; P = 0.26).
Deletions of 13q in MM progressing from MGUS
We studied BM plasma cells from 17 patients with MM after pre-existing MGUS (median time to progression, 65 months; range, 22-150 months), using the RB1-specific probe as marker for 13q14. In nine of the 17 patients (52.9%), a monoallelic deletion of RB1 was detected by FISH. Samples from both the MGUS and the MM stage of the disease were available in seven patients. Three patients were found to have the RB1 deletion, which was already present at the MGUS stage (deletions of RB1 in 17%, 25%, and 27% of plasma cells, respectively). MM plasma cells from these patients had a similar frequency of RB1-deleted cells (16%, 23%, and 40%, respectively). In the remaining four patients, FISH for RB1 revealed a normal pattern in both MGUS and MM plasma cells.
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Discussion
According to several recent observations, abnormalities involving chromosome 13q are a critical event in MM, being significantly associated with inferior outcome. [3] [4] [5] [6] By interphase FISH, deletions of 13q14 can be detected in 33-52% of patients with newly diagnosed MM, 5, 6, [17] [18] [19] and in up to 73% of patients with relapsed disease. 6 We present here data showing that deletions of 13q14 are also frequently present in MGUS plasma cells (13 of 29 patients with MGUS; 45%). Detailed analysis of 13q revealed that both small interstitial deletions and gross chromosomal aberrations affecting the entire 13q arm may occur. In this series, there was no apparent minimally deleted region which could provide further information about a candidate gene or genes that may be most relevant for the pathogenesis of monoclonal gammopathies, but this question is difficult to address in MGUS.
Any deletion that is detected by FISH needs to be interpreted with caution, since apparent loss of hybridization signals may also reflect insufficient hybridization conditions. Similarly to our previous study, 6 we have performed dualcolor hybridizations combining the 13q-specific probe with a reference probe (chromosome 11-centromeric probe), and only cells with у2 signals with the reference probe were evaluated. The observer needs to be aware of the fact that a pericentromeric probe results in brighter signals than a regionspecific probe and is thus easier to score. According to our experience in MM, this FISH assay proved to be very reliable for detection of a 13q deletion, since in all cases with informative metaphases (30 patients), interphase FISH results were confirmed by metaphase cytogenetics. 6 Such confirmatory conventional cytogenetic results are not available from patients with MGUS. Due to the reliability of the described FISH procedure and the observation of deletions significantly above the stringently defined background values, we interprete our findings as true evidence for 13q deletions in MGUS plasma cells.
Our findings are in good agreement with results recently presented by Avet-Loiseau et al, 19 who reported 13q14 deletions as detected by the D13S319 probe in four of 19 patients (21%) with MGUS. We observed D13S319 to be deleted in eight out of 27 MGUS patients (29.6%). We have also shown that chromosomal loci adjacent to D13S319 may be involved in deletions of 13q14, which explains the overall higher frequency of 13q deletions reported by us compared to the results by Avet-Loiseau et al. 19 In both studies, deletions of 13q14 were observed to occur in only a proportion of plasma cells. Therefore, it remains questionable whether or not the chromosome 13q deletion represents a primary chromosomal abnormality in monoclonal gammopathies. Besides numerical abnormalities, which are usually a random, secondary event reflecting genetic instability, MGUS plasma cells may also harbor translocations involving the immunoglobulin heavy-chain locus at 14q32. 19, 20 However, any sequence of chromosomal events occurring in monoclonal gammopathies and MM has yet to be determined.
From a clinical perspective, MGUS represents a benign condition which may remain stable over many years, and most individuals succumb from diseases that are unrelated to the monoclonal gammopathy. However, after prolonged follow-up, it has been recognized that a sizeable fraction of patients progresses to MM or another malignant lymphoproliferative disorder (actuarial rate 33% at 20 years). 21 It is thus of clinical relevance to determine predictive factors that allow identification of these patients at risk of progression. Several parameters have been reported to be associated with a predisposition of transformation of MGUS patients. These included the presence of an IgA serum paraprotein, a serum M-component greater than 1.5 g/dl, more than 5% plasma cells in the bone marrow, and evidence for excessive bone resorption. [22] [23] [24] At the molecular level, it has been reported that alterations of interleukin-6 receptor, lck and c-myc genes may precede progression from MGUS to MM. 25 Results from a recent study suggested that the presence of a chromosome 13 abnormality (deletion of D13S319) is associated with an increased rate of progression from MGUS to MM. 19 This was based upon the observation that 14 of 20 patients (70%) with MM after a preexisting MGUS had a deletion of 13q14 as opposed to 29 of 95 patients (31%) with 'de novo' MM. 19 In our series of 17 patients with MM progressing from MGUS, nine patients (53%) had evidence for a deletion of 13q14 as detected with the RB1 probe. This is not different from the overall frequency of RB1 deletions (46%) previously observed in our population of 104 patients with MM. 6 We are unable to define the incidence of pre-existing MGUS in this patient population since in almost all patients appropriate laboratory tests have not been performed prior to the diagnosis of MM. When we looked at paired specimens from seven patients, ie plasma cells from both the MGUS and MM phases of the disease, RB1 deletions were detected in three patients whereas the remaining four patients had a normal RB1 status. Unfortunately, only a limited number of BM cells was available from the MGUS phase, which allowed us to use the RB1 probe only. Despite this limitation, our collective results are not suggestive for an association between the presence of the chromosome 13q abnormality and risk of progression from MGUS to MM. Nevertheless, deletion of 13q14 defines a distinct entity of MM with unique biological and clinical features. Further prospective follow-up of patients with MGUS will be required to definitely answer the question whether or not the presence of a 13q deletion may represent a risk factor for progression from MGUS to MM.
